Thymosin alpha-1 dosage chart by source

The first row is a label, the next two are published studies, and the last is what vendors describe. The label and the dialysis study agree on 1.6 mg twice a week, the second study adds a daily first week, and the vendor range sits just around the label dose. Background on the peptide is on the thymosin alpha-1 page.

Research thymosin alpha-1 is sold as a freeze-dried powder, commonly in 5 mg and 10 mg vials. You mix it with bacteriostatic water, which is sterile water with a preservative so one vial can be drawn from more than once. Per the Zadaxin product information, the approved product is different: a 1.6 mg vial mixed with 1 mL of the diluent that comes with it, so a dose is the whole vial.

The tables show units on a U-100 syringe, which holds 100 units in 1 mL, for 1, 2 and 3 mL of water. The two amounts are the label dose, 1.6 mg, and the top of the vendor range, 2 mg.

Units are math from the chart amounts, rounded in the strength column. "Over one syringe" means the draw is more than the 100 units a 1 mL syringe holds, so 1 or 2 mL suits a 5 mg vial better.

More water makes a bigger, easier draw, and a 10 mg vial with 1 mL gives only 16 units for a 1.6 mg dose. For any other vial, water or amount, the reconstitution calculator does the same math.

Twice a week. The label gives two injections a week, and the dialysis study did the same. The second study's schedule is a separate pattern, 1.6 mg every day for the first 7 days and then twice a week.

Six to twelve months on the label. The Zadaxin product information sets 6 to 12 months for hepatitis B. For hepatitis C it describes studies that ran it twice a week alongside interferon for 6 to 12 months. The studies in the chart ran 8 weeks. For the vendor range, no source sets a length.

Under the skin only. The label says subcutaneous, and not into a vein. Vendor pages usually describe the belly or thigh, with the spot rotated.

Smaller bodies. The label gives 40 mcg per kg of body weight, instead of 1.6 mg, for anyone under 88 pounds. For an 80 pound person, that works out to about 1.45 mg.

Time of day. No study or label sets one.

For planning, 8 weeks at 1.6 mg twice a week is 16 doses and 25.6 mg. A full 6-month label course is 52 doses and 83.2 mg. Compare vendors on price per milligram against a total like that, not on the price of one vial.

A mixed vial goes on a 28-day clock in the fridge the day water goes in, however much of it gets used. A 10 mg vial holds 6 full doses of 1.6 mg, which covers 21 days at two a week, with 400 mcg left over, so it fits inside the clock. A 5 mg vial holds 3 full doses and covers 10.5 days. At 2 mg, a 10 mg vial gives 5 doses over 17.5 days, and a 5 mg vial only 2 doses, one week.

Eight weeks at 1.6 mg twice a week is 16 doses, which takes three 10 mg vials or six 5 mg vials. The daily first week is 7 doses, one more than a 10 mg vial holds, so it starts a second vial, and a 21-dose course with that week takes four 10 mg vials. The approved product avoids all this because it's one dose per vial, mixed right before use.

Community reports describe pairing it with KPV or VIP, each on its own schedule over the same weeks. No study tests any of these pairings. The twice-weekly schedule here won't line up with a once-a-day one, so people run them as separate injections.

These are the effects the product information lists and what people report, not findings from a study of research vials.

Soreness or redness where you injected. The label lists discomfort where you injected as the main effect, and redness as rare. People rotate the spot between doses.

Feeling flu-ish after the first few doses. Reported now and then in community reports, and usually described as passing. People watch whether it clears within the first week or two.

No change after a season. The question people ask is whether they get ill less often, and that takes months to judge. No study has tested it for fewer illnesses in healthy adults, so a quiet result isn't a clear sign either way.